Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA's Rare Diseases Program Not Expected To Change With Drug Office Reorg

Jun 28 2018

• By Derrick Gingery

FDA entrance sign 2016

Related Content

FDA Orphan Approval Flexibility Remains Steady As Pressure Increases

Oct 27 2014

Rare Disease Integration Into FDA Reviews Will Grow Under PDUFA VI

Jul 18 2016

Orphan Drug Reviews: Industry Wants FDA To Move Out Of Its Comfort Zone

Jul 05 2010

New OND Director Could Be Hired Within Six Months, Woodcock Says

May 07 2018

Another Reorg For US FDA Drug Office: Dispute Resolution Program Moves Out

Jun 07 2018

BIO Notebook Day 3: ARM Launches Foundation To Educate Public About Gene And Cell Therapies

Jun 07 2018

Office Of New Drugs Reorg Is Bigger Than Expected: US FDA Adds 11 Review Divisions

Jun 04 2018

Additional Topics

United States Review Pathway Rare Diseases Regulation FDA BioPharmaceutical

More from Review Pathways

More from Pathways & Standards

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.